Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NIK-333(Peretinoin) PhaseⅢ Study Investigation of the Efficacy and Safety to Suppress Recurrence of Hepatitis C Virus(HCV)-Positive Hepatocellular Carcinoma(HCC), Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel-group Study

NCT01640808 is registered in ClinicalTrials.gov with Kowa Company, Ltd. as lead sponsor.

NCT NCT01640808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01640808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NIK-333(Peretinoin) PhaseⅢ Study Investigation of the Efficacy and Safety to Suppress Recurrence of Hepatitis C Virus(HCV)-Positive Hepatocellular Carcinoma(HCC), Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel-group Study
Lead sponsor
Kowa Company, Ltd.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2012
Completion date
November 30, 2016
Enrollment
616 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic neoplasm malignant recurrent